Tecovirimat Safe in Monkeypox, but Efficacy Is Less Clear
Tecovirimat (Tpoxx) was well tolerated among patients with monkeypox virus infection, though its efficacy in monkeypox is currently unclear, CDC researchers said. Among over 300 patients taking tecovirimat under the FDA-regulated Expanded Access Investigational New Drug (EA-IND) protocol, 6.9% were hospitalized after symptom onset, with a median duration of hospitalization of 4 days, reported Farrell […]